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This position statement originated from a working group meeting convened on April 15, 2015, by the NHLBI and incorporates
follow-up contributions by the participants as well as other thought leaders subsequently consulted, who together represent
research fields relevant to all branches of the NIH. The group was deliberately composed not only of individuals with a current
research emphasis in the glycosciences, but also of many experts from other fields, who evinced a strong interest in being
involved in the discussions. The original goal was to discuss the value of creating centers of excellence for training the next
generation of biomedical investigators in the glycosciences. A broader theme that emerged was the urgent need to bring the
glycosciences back into the mainstream of biology by integrating relevant education into the curricula of medical, graduate,
and postgraduate training programs, thus generating a critical sustainable workforce that can advance the much-needed
translation of glycosciences into a more complete understanding of biology and the enhanced practice of medicine.

Background and current status

Every living cell in nature that has emerged from more than 3 billion years of biological evolution is composed of nucleic acids,
proteins, lipids, metabolites, and glycans, and each of these comAuthorship note: R. Sarkar is the NHLBI program representative. A. Varki and R. Schnaar
co-chaired the working group.
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ponents remains essential to all life forms. Until the 1970s, the
study of glycans was thus an integral part of the exploration of all
biological systems, generating major advances in fields as diverse
as hematology, microbiology, metabolism, and material sciences.
With the rapid advent of powerful insights and tools, the study of
nucleic acids and proteins came to dominate the molecular biology revolution of subsequent decades. While similar revolutions in
the biological exploration of lipids and metabolites have now followed, the study of glycans has been left far behind. The reasons
for this omission are many, but can be broadly ascribed to the far
greater complexity and diversity of this class of molecules and the
related lack of comparable tools for their exploration. In analogy to
the situation in cosmology, the “standard model” for approaching
biological systems now largely excludes glycans, which have effectively become the “dark matter” of the biological universe: critijci.org   Volume 126   Number 2   February 2016
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cal for a full understanding of biology and yet routinely ignored.
While a small number of scientists persisted in the in-depth study
of glycans (resulting in a specialized field called glycobiology), an
entire generation of mainstream biologists was trained with little
knowledge of the structure, analysis, or functions of glycans or
even of the terminology required for discussing them. This anomaly in the history of the biological sciences has since trickled down
to all levels of education, resulting in lost opportunities for a more
complete understanding of the biology and pathology of living systems, which would also greatly benefit therapeutic development
and medical practice. Very few scientists are thus now trained in
understanding glycosciences, and studies of glycans have also lost
prominent attention from major journals and grant review groups
or recognition by honors and awards.
Recognizing this stark deficiency, the NIH, the National Science Foundation (NSF), the Department of Energy (DOE), the
FDA, and the Howard Hughes Medical Institute (HHMI) commissioned an enquiry into the situation by the National Research
Council (NRC) of the National Academies (1). The resulting 2012
report, entitled Transforming Glycoscience: A Roadmap for the
Future, noted the following:
Glycoscience is a highly interdisciplinary field that aims to
better understand the structures and functions of glycans
and how they can be used. It is a global field with a dedicated community of researchers in the United States and
abroad. Glycoscientists do not have a single training/education background. They come from various fields, including physiology and developmental biology, where glycans
are involved in processes such as cell movement and tissue development. They are in medicine, where glycans are
involved in the development and progression of chronic and
infectious diseases. In microbiology, glycans are key players
in interactions among and between microbes and host cells.
Glycoscientists are chemists developing new synthetic and
analytical methods for glycans, and biochemists working to
understand glycan synthesis and metabolism. In materials
science, glycans can be used as polymeric materials having
a wide range of properties. In computational science and
informatics, modeling studies and the effective analysis of
large amounts of experimental data are also necessary to
better understanding glycans.
In the area of human health, the NRC report also noted that
(a) glycans are directly involved in the pathophysiology of every
major disease; (b) additional knowledge from glycosciences will
be needed to realize the goals of personalized medicine and to
take advantage of the substantial investments in human genome
and proteome research; and (c) glycans are increasingly important
in pharmaceutical development.
Among the resulting roadmap goals in the NRC report were
specific comments and recommendations regarding enhanced
training in the glycosciences.
The committee notes that there is widespread lack of understanding and appreciation of glycoscience in the scientific
and medical communities and among the general pub406
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lic. Glycans are integral components of living organisms,
whether human, animal, plant, or microbe, and glycan
products have applications in health, energy, and materials
science. The committee concludes that integrating glycoscience into relevant disciplines in high school, undergraduate,
and graduate education, and developing curricula and standardized testing for science competency would increase
public as well as professional awareness.
Within 10 years, glycoscience will be integrated and
taught at every level wherever it is relevant to understand
the scientific content.
In response to the overall NRC report, the NIH Office of Strategic Coordination via the NIH Director’s Common Fund released
a series of requests for applications with the following program
initiatives: (a) developing methods and technologies for synthesis
of biomedically relevant carbohydrates; (b) developing accessible
tools for probing and analyzing carbohydrates and their interaction partners; (c) developing data integration and analysis tools.
Notably lacking was any direct support for training in glycosciences. It was the charge of this working group to consider further
the need for mechanisms to address this unmet need.

Working group objectives

The working group defined its objectives as follows: “Discuss
the value and mechanisms of training the next generation of
biomedical investigators in the glycosciences, with the goal of
bringing glycoscience back into the mainstream of biology — by
generating a critical sustainable workforce that will advance the
translation of glycosciences in biology and medicine, and help
integrate glycoscience education into the curricula of medical
and graduate schools” (1).

Definition of needs and opportunities

There is increasing recognition of the diverse roles and uses of
glycans in biology and medicine. Yet glycoscience has not gained
much attention in the mainstream of biology and is viewed as
a niche research area with relatively few qualified researchers.
While high school, undergraduate, and graduate students learn
about nucleic acids, proteins, lipids, and metabolites, their competency in understanding the chemistry and biology of glycans is
now conspicuously deficient. Also, compared with the NIH investments made in understanding other major components of life,
glycans have received very little attention. This chasm needs to be
addressed by training a new generation of biomedical researchers
for whom glycans are an integral part of their mainstream thinking.
The working group discussed the role of glycosciences in the
discovery process. One theme that repeatedly arose was that the
field is indeed poorly represented among researchers and lecturers at most biomedical research institutions. Despite this, some
great advances in biomedical discovery in several areas, including
hematology, immunology, infectious diseases, genetic diseases,
cancer, and neuroscience, have been facilitated by the coincidental proximity of key investigators to colleagues who understood
the glycoscience aspects of their research and also had the motivation and tools to apply this understanding to the biomedical challenges at hand. Without such serendipitous input, the discoveries
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Building a workforce versed in glycoscience
Add basic knowledge of glycoscience to national standardized tests to encourage inclusion of the discipline in teaching.
Include more key concepts of glycoscience in undergraduate and graduate level textbooks in the biomedical sciences (e.g., cell
biology, biochemistry).
Encourage opportunities for hands-on training in glycoscience experimentation and discovery.
“Democratize” glycoscience for nonspecialists. Train life scientists and clinicians to be conversant in the discipline, even if they
never become experts.
Encourage glycoscientists to seek opportunities to lecture outside of the field in order to disseminate knowledge, break down
barriers, and motivate others to embrace glycoscience within their biomedical world view.
Integrate glycosciences in their appropriate place in all major chemical and biomedical disciplines, instead of as a field apart.
Make glycobiology integral to biology and glycochemistry integral to biochemistry and organic chemistry.
Emphasize the attractive biological functional aspects of the field to motivate students and colleagues to delve more deeply into
its details.
Promote existing resources (textbooks, online content) to help established faculty expand glycoscience teaching.
Leverage opportunities from successful pharmaceutical developments that have been highlighted online and in the popular
press to emphasize positive outcomes arising from glycosciences.
Encourage training of those at regulatory and governmental bodies in the opportunities of glycosciences.

would have been delayed or not been made at all. Furthermore,
without knowledgeable faculty in many biomedical educational
institutions, there is a striking absence of lectures and seminars in
the area. This creates a feed-forward self-perpetuating deficit of
knowledge in the field. Glycosciences are not taught (or are barely
taught) at many institutions, leading to a generation of otherwise
superbly trained physicians and biomedical scientists who are
nonetheless unfamiliar with language and basic knowledge in this
key aspect of all biological systems. When such individuals enter
the biomedical workforce, whether in academia, science administration, or the drug discovery and diagnostics industries, they are
unlikely to grasp the implications of glycosciences for their own
work or that of others. They are also unlikely to sufficiently emphasize glycoscience training in the curricula they develop. Generation after generation, we are now losing ground with regard to the
potential of this discipline.
For those few who do make glycosciences their career, the
rewards of discovery are hard fought, often against significant
resistance from editorial boards, grant review committees, and
biomedical investment groups who lack the basic knowledge of
glycosciences necessary to understand the goals and opportunities at hand. Despite these challenges, significant advances have
been translated from glycoscience discovery to the clinic. For
example, many groundbreaking biologicals now in the clinic,
including cytokines, such as erythropoietin and all monoclonal
antibodies, are glycoproteins that are expressly dependent on
their glycans for pharmacodynamic and pharmacokinetic properties, stability, and function. Important vaccines have been developed based on microbial glycans, such as pneumococcus and haemophilus polysaccharides. In addition, glycomimetic compounds

developed to target glycan-binding sites on functional glycanbinding proteins are now showing promise for syndromes such
as sickle cell crises, with more under development by the biotech
and pharmaceutical industries.
A consensus arose on the committee that the basic and therapeutic significance of glycosciences has already been well established, with more progress on the way. But maintaining and accelerating translation in glycosciences will require a reversal of the
ongoing year-over-year deficit of knowledge in this area among
most biomedical scientists. One solution will be to populate major
academic research centers, research institutes, government laboratories, and drug development companies with colleagues who
have experience and knowledge in the glycosciences. But the pool
of such individuals is currently very small. Potential resources
that will help correct this situation are discussed further below. In
addition, we believe several key actions are required to bring more
of our trainees and colleagues on board, as detailed in Building a
workforce versed in glycoscience.

Developing resources for glycoscience training

It is the consensus of the working group that bottom-up rebuilding of the glycoscience enterprise with a long-range perspective
will enhance all aspects of biology and medicine. In particular,
investing resources in populating the biomedical research enterprise at all levels with individuals trained in the discipline will
have outsized positive effects on discovery. The presence of
trained glycoscientists as researchers, faculty members, science
administrators, reviewers, journal editors, biomedical investors, patent officers, and consultants will reverse the “glycoscience desert” at many institutions and levels and begin to infuse
jci.org   Volume 126   Number 2   February 2016

407

Downloaded from http://www.jci.org on April 5, 2016. http://dx.doi.org/10.1172/JCI85905

PERSPECTIVE

The Journal of Clinical Investigation  

Expanding support for glycoscience training
Create centers of excellence for training the next generation of biomedical investigators in the glycosciences. As an example,
establish new K12 and K01 mechanisms to support supervised transition of biomedical scientists late in training to independent careers with full integration of the glycosciences. It is anticipated that such awards would incentivize established
experts to recruit and mentor young colleagues and to expand the presence of independent glycoscience-knowledgeable
investigators across the biosciences.
Provide independent support for those with recent glycoscience-related doctorates to pursue glycoscience-related postdoctoral
research collaboratively in laboratories that are not traditionally glycoscience focused. This support will encourage those
with glycoscience needs to access expertise and expand the knowledge base of their laboratories in this discipline.
Create a collaborative research award for a laboratory in need of glycoscience expertise to work with an established glycoscience laboratory. This could perhaps take the form of supplements to existing R01 grants of the two labs in question. This
mechanism should be considered by all NIH institutes whose portfolios are relevant to glycosciences.
Support fellowships for undergraduate and medical students to perform summer projects in glycoscience laboratories.
Encourage NIH institutes to include glycoscience training in the form of special-emphasis training grants.
Expand upon the few existing immersive glycoscience training courses to bring investigators who are not in the field up to speed
in basic knowledge of glycosciences. A Gordon Conference or Wood’s Hole/Cold Spring Harbor–style week-long or multiweek format, already successful in advanced glycoscience courses in Europe, could be a model. Multidisciplinary meetings
or workshops emphasizing the roles of glycans in fields such as neuroscience, cancer, immunity, infectious diseases, blood
and vascular systems, etc. would also be of value.
Encourage established glycoscientists to get more involved in basic undergraduate and graduate courses, ranging from organic
chemistry to structural biology, physiology, and molecular and cellular biology.

knowledge about glycans into teaching, research, and the knowledge base of physicians and scientists.
As demonstrated by the successes of the current NHLBIsponsored Programs of Excellence in Glycoscience mechanism,
a quick way to achieve this goal in the short term is to develop
programs of supervised research training to bring more young
investigators at the postdoctoral and starting faculty level into the
field. This type of intensive immersion training of those late in
their training careers has been shown to have a significant positive outcome in keeping trainees in the field when they embark on
independent careers. We propose that specific steps can be taken
to address this gap for young investigators, as detailed in Expanding support for glycoscience training.

Concluding statement

Glycans are ubiquitous in all living cells and organisms, where they
serve essential functions, ranging from acting as structural components to regulating physiological and pathological processes. Evidence clearly indicates that glycans represent a largely untapped
resource for biological discovery as well as unanticipated therapeutic opportunities. However, among the major classes of biomolecules, glycans have generally received the least attention, in
part due to a self-perpetuating underappreciation of their biologic
impact, their inherent structural complexity, and the lack of tools
408
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to synthesize and analyze them. This is changing, with new capabilities and new resources focused on enhancing research tools in
glycosciences. While such investments are very worthwhile, they
will fall short of their promise unless the stark deficit in training
and knowledge in the field is vigorously addressed. The committee feels that using a bottom-up approach of emphasizing training
and incentivizing an increased number of young investigators will
begin to reverse the self-perpetuating underutilization of glycosciences in biomedical sciences, resulting in outsized benefits
towards enhancing knowledge and tools in the discipline and thus
more effectively meeting the mandates of the NIH in particular
and the biomedical research enterprise in general.
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